{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:10:48Z","timestamp":1784902248819,"version":"3.55.0"},"reference-count":88,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Cannabis sativa contains more than 120 phytocannabinoids, with \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the best characterized. This review synthesizes preclinical and clinical evidence on hemp-derived extracts, cannabinoids, and active compounds. THC primarily acts as a partial agonist at cannabinoid receptor type 1 (CB1) and type 2 (CB2), producing psychoactive, appetite-stimulating, antiemetic, and analgesic effects. CBD is non-intoxicating and has a multimodal profile involving CB1 negative allosteric modulation, CB2 inverse agonism or antagonism, inhibition of anandamide inactivation, and activity at 5-HT1A receptors, transient receptor potential channels, GPR55, and peroxisome proliferator-activated receptor gamma. Preclinical models of Parkinson\u2019s disease, Alzheimer\u2019s disease, Huntington\u2019s disease, epilepsy, and pain support anti-inflammatory, antioxidant, anti-excitotoxic, and glial-modulating mechanisms, but clinical translation remains uneven. The strongest evidence supports FDA-approved cannabidiol for Lennox\u2013Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex, and THC-based agents for refractory chemotherapy-induced nausea and vomiting and AIDS-related anorexia. Moderate-certainty evidence supports nabiximols for multiple sclerosis spasticity and small benefits in selected chronic neuropathic pain populations. Evidence remains insufficient or negative for acute pain, insomnia, most psychiatric disorders, and many promoted indications. Key risks include cannabis use disorder, cognitive and psychiatric effects, cardiovascular events, sedation, high-dose CBD hepatotoxicity, and drug interactions. Rigorous, long-term, product-standardized trials are needed.<\/jats:p>","DOI":"10.3390\/ph19081151","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:53:26Z","timestamp":1784901206000},"page":"1151","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuropharmacology of Cannabinoids: A Comprehensive Review of Preclinical and Clinical Evidence for Hemp-Derived Extracts and Active Compounds"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8280-4015","authenticated-orcid":false,"given":"Charles A.","family":"Odonkor","sequence":"first","affiliation":[{"name":"Department of Orthopedics and Rehabilitation, Division of Physiatry, Interventional Pain Medicine, Yale New Haven Hospital and Yale University School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5849-0747","authenticated-orcid":false,"given":"David A.","family":"Karpe","sequence":"additional","affiliation":[{"name":"University of New England College of Osteopathic Medicine, Biddeford, ME 04005, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7682-5297","authenticated-orcid":false,"given":"Muhammad Uzair","family":"Siddique","sequence":"additional","affiliation":[{"name":"Department of Orthopedics and Rehabilitation, Yale University School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Abd-Elsayed","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Wisconsin, Madison, WI 53792, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jama.2025.19433","article-title":"Therapeutic Use of Cannabis and Cannabinoids: A Review","volume":"335","author":"Hsu","year":"2026","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neuron.2022.12.022","article-title":"THC and CBD: Similarities and Differences Between Siblings","volume":"111","author":"Stella","year":"2023","journal-title":"Neuron"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J. Am. Chem. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"ref_6","first-page":"598","article-title":"Cannabis Essentials: Tools for Clinical Practice","volume":"104","author":"Sazegar","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_7","unstructured":"U.S. Food and Drug Administration (2026). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s42238-021-00062-4","article-title":"The Biosynthesis of the Cannabinoids","volume":"3","author":"Tahir","year":"2021","journal-title":"J. Cannabis Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"104822","DOI":"10.1016\/j.phrs.2020.104822","article-title":"Cannabis sativa: Much More Beyond \u0394-9-Tetrahydrocannabinol","volume":"157","author":"Alves","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pellati, F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S., and Corsi, L. (2018). Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. BioMed Res. Int., 2018.","DOI":"10.1155\/2018\/1691428"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-57369-0_3","article-title":"Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review","volume":"1264","author":"Hallak","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1111\/bph.15185","article-title":"A Systematic Review of Minor Phytocannabinoids with Promising Neuroprotective Potential","volume":"177","author":"Stone","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107878","DOI":"10.1016\/j.pharmthera.2021.107878","article-title":"Therapeutic Potential of Cannabidivarin for Epilepsy and Autism Spectrum Disorder","volume":"226","author":"Zamberletti","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1124\/jpet.124.002166","article-title":"The Potential of Cannabichromene (CBC) as a Therapeutic Agent","volume":"391","author":"Sepulveda","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2478\/acph-2021-0021","article-title":"Cannabigerol and Cannabichromene in Cannabis sativa L.","volume":"71","author":"Kreft","year":"2021","journal-title":"Acta Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113458","DOI":"10.1016\/j.fct.2022.113458","article-title":"Evaluation of the Anti-Inflammatory Effects of Selected Cannabinoids and Terpenes from Cannabis sativa Employing Human Primary Leukocytes","volume":"170","author":"Blevins","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1038\/s41598-021-87740-8","article-title":"Cannabis sativa Terpenes Are Cannabimimetic and Selectively Enhance Cannabinoid Activity","volume":"11","author":"LaVigne","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Weston-Green, K., Clunas, H., and Jimenez Naranjo, C. (2021). A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.583211"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Alfieri, A., Di Franco, S., Maffei, V., Sansone, P., Pace, M.C., Passavanti, M.B., and Fiore, M. (2025). Phytochemical Modulators of Nociception: A Review of Cannabis Terpenes in Chronic Pain Syndromes. Pharmaceuticals, 18.","DOI":"10.20944\/preprints202506.1861.v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.tplants.2020.04.007","article-title":"Cannabis Phytomolecule \u2018Entourage\u2019: From Domestication to Medical Use","volume":"25","author":"Koltai","year":"2020","journal-title":"Trends Plant Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2174\/1381612829666221103093542","article-title":"Entourage Effect and Analytical Chemistry: Chromatography as a Tool in the Analysis of the Secondary Metabolism of Cannabis sativa L.","volume":"29","author":"Desimone","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the Expanded Endocannabinoid System in Neurological Disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_23","first-page":"607","article-title":"Review of the Endocannabinoid System","volume":"6","author":"Lu","year":"2021","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11916-022-01008-y","article-title":"Dorsal Column Stimulation and Cannabinoids in the Treatment of Chronic Nociceptive and Neuropathic Pain: A Review of the Clinical and Pre-Clinical Data","volume":"26","author":"Odonkor","year":"2022","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bia\u0142o\u0144, M., K\u0119dziora, M., and Starowicz, K. (2026). Cannabidiol in Neurology: Current Insights and Translational Perspectives. Pharmaceuticals, 19.","DOI":"10.3390\/ph19020330"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/npp.2017.209","article-title":"Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and \u0394-9-Tetrahydrocannabinol","volume":"43","author":"Boggs","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8762","DOI":"10.1523\/JNEUROSCI.0708-19.2019","article-title":"Cannabidiol Counteracts the Psychotropic Side-Effects of \u0394-9-Tetrahydrocannabinol in the Ventral Hippocampus Through Bidirectional Control of ERK1-2 Phosphorylation","volume":"39","author":"Hudson","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41386-018-0282-7","article-title":"\u0394-9-Tetrahydrocannabinol and Cannabidiol Produce Dissociable Effects on Prefrontal Cortical Executive Function and Regulation of Affective Behaviors","volume":"44","author":"Szkudlarek","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12640-020-00277-y","article-title":"A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT1A Receptors","volume":"39","author":"Echeverry","year":"2021","journal-title":"Neurotox. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1152\/physrev.00049.2021","article-title":"Cannabinoid Treatments in Epilepsy and Seizure Disorders","volume":"104","author":"Devinsky","year":"2024","journal-title":"Physiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1474-4422(19)30032-8","article-title":"Safety, Efficacy, and Mechanisms of Action of Cannabinoids in Neurological Disorders","volume":"18","author":"Friedman","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1161\/STR.0000000000000396","article-title":"Use of Marijuana: Effect on Brain Health: A Scientific Statement from the American Heart Association","volume":"53","author":"Testai","year":"2022","journal-title":"Stroke"},{"key":"ref_33","unstructured":"U.S. Food and Drug Administration (2025). Epidiolex (Cannabidiol) Prescribing Information."},{"key":"ref_34","first-page":"332","article-title":"Use of Phytocannabinoids in Animal Models of Parkinson\u2019s Disease: Systematic Review","volume":"103","author":"Alves","year":"2024","journal-title":"Neurotoxicology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcp.2018.08.016","article-title":"Cannabinoid Pharmacology\/Therapeutics in Chronic Degenerative Disorders Affecting the Central Nervous System","volume":"157","author":"Aymerich","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Urmeneta-Ort\u00edz, M.F., Tejeda-Mart\u00ednez, A.R., Gonz\u00e1lez-Reynoso, O., and Flores-Soto, M.E. (2024). Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson\u2019s Disease. Park. Dis., 2024.","DOI":"10.1155\/2024\/5519396"},{"key":"ref_37","first-page":"81","article-title":"Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s Diseases","volume":"1264","author":"Lillo","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e160499","DOI":"10.5812\/ijpr-160499","article-title":"Cannabidiol Extracted from Cannabis sativa L. Plant Shows Neuroprotective Impacts Against 6-OHDA-Induced Neurotoxicity via Nrf2 Signal Transduction Pathway","volume":"24","author":"Esfandi","year":"2025","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Coles, M., Steiner-Lim, G.Z., and Karl, T. (2022). Therapeutic Properties of Multi-Cannabinoid Treatment Strategies for Alzheimer\u2019s Disease. Front. Neurosci., 16.","DOI":"10.3389\/fnins.2022.962922"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Calina, D., Buga, A.M., Mitroi, M., Buha, A., Caruntu, C., Scheau, C., Bouyahya, A., El Omari, N., El Menyiy, N., and Docea, A.O. (2020). The Treatment of Cognitive, Behavioural and Motor Impairments from Brain Injury and Neurodegenerative Diseases through Cannabinoid System Modulation\u2014Evidence from In Vivo Studies. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082395"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s13311-015-0381-7","article-title":"Cannabinoids in Neurodegenerative Disorders and Stroke\/Brain Trauma: From Preclinical Models to Clinical Applications","volume":"12","author":"Moro","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.124.002212","article-title":"Select Minor Cannabinoids from Cannabis sativa Are Cannabimimetic and Antinociceptive in a Mouse Model of Chronic Neuropathic Pain","volume":"391","author":"Schwarz","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in Patients with Seizures Associated with Lennox\u2013Gastaut Syndrome (GWPCARE4): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-Drug Interaction Between Clobazam and Cannabidiol in Children with Refractory Epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.23.02596","article-title":"Cannabis and Cannabinoids in Adults with Cancer: ASCO Guideline","volume":"42","author":"Braun","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.23.01836","article-title":"Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II\/III Trial","volume":"42","author":"Grimison","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","article-title":"Oral THC:CBD Cannabis Extract for Refractory Chemotherapy-Induced Nausea and Vomiting: A Randomised, Placebo-Controlled, Phase II Crossover Trial","volume":"31","author":"Grimison","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_51","unstructured":"National Comprehensive Cancer Network (2026). NCCN Clinical Practice Guidelines in Oncology: Antiemesis, Version 1.2026, NCCN."},{"key":"ref_52","unstructured":"U.S. Food and Drug Administration (2026). Dronabinol (Marinol) Prescribing Information."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"n1034","DOI":"10.1136\/bmj.n1034","article-title":"Medical Cannabis or Cannabinoids for Chronic Non-Cancer and Cancer Related Pain: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"374","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.7326\/M21-4520","article-title":"Cannabis-Based Products for Chronic Pain: A Systematic Review","volume":"175","author":"McDonagh","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"230","DOI":"10.7326\/ANNALS-25-03152","article-title":"Cannabis-Based Products for Chronic Pain: An Updated Systematic Review","volume":"179","author":"Chou","year":"2026","journal-title":"Ann. Intern. Med."},{"key":"ref_56","first-page":"CD012182","article-title":"Cannabis-Based Medicines for Chronic Neuropathic Pain in Adults","volume":"1","author":"Welsch","year":"2026","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/ANNALS-24-03319","article-title":"Cannabis or Cannabinoids for the Management of Chronic Noncancer Pain: Best Practice Advice from the American College of Physicians","volume":"178","author":"Kansagara","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and Cannabinoids for the Treatment of People with Chronic Noncancer Pain Conditions: A Systematic Review and Meta-Analysis of Controlled and Observational Studies","volume":"159","author":"Stockings","year":"2018","journal-title":"Pain"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/1060028020930189","article-title":"Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature","volume":"54","author":"Inglet","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"108250","DOI":"10.1016\/j.phrs.2026.108250","article-title":"Efficacy of Sativex\u00ae on Pain, Spasticity, and Disability in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis","volume":"229","author":"Nucera","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., and Dwan, K. (2022). Cannabis and Cannabinoids for Symptomatic Treatment for People with Multiple Sclerosis. Cochrane Database Syst. Rev., 2022.","DOI":"10.1002\/14651858.CD013444.pub2"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Sacco, R., Riccitelli, G.C., Disanto, G., Bogousslavsky, J., Cavelti, A., Czell, D., Kamm, C.P., Kliesch, U., Ramseier, S.P., and Gobbi, C. (2024). Effectiveness, Safety and Patients\u2019 Satisfaction of Nabiximols (Sativex) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13102907"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11910-018-0859-x","article-title":"Cannabinoids for Treatment of MS Symptoms: State of the Evidence","volume":"18","author":"Rice","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bcpt.13997","article-title":"Therapeutic Applicability of Cannabidiol and Other Phytocannabinoids in Epilepsy, Multiple Sclerosis and Parkinson\u2019s Disease and in Comorbidity with Psychiatric Disorders","volume":"134","author":"Sampaio","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Na\u00efve Social Phobia Patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"116049","DOI":"10.1016\/j.psychres.2024.116049","article-title":"Therapeutic Potential of Cannabidiol (CBD) in Anxiety Disorders: A Systematic Review and Meta-Analysis","volume":"339","author":"Han","year":"2024","journal-title":"Psychiatry Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"104941","DOI":"10.1016\/j.neubiorev.2022.104941","article-title":"Cannabinoid Treatments for Anxiety: A Systematic Review and Consideration of the Impact of Sleep Disturbance","volume":"143","author":"Narayan","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1515\/revneuro-2023-0078","article-title":"Subjective, Behavioral and Neurobiological Effects of Cannabis and Cannabinoids in Social Anxiety","volume":"35","author":"Lemes","year":"2024","journal-title":"Rev. Neurosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jamainternmed.2025.8215","article-title":"Cannabis and Mental Health: A Review","volume":"186","author":"Kansagara","year":"2026","journal-title":"JAMA Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., and Firth, J. (2020). Medicinal Cannabis for Psychiatric Disorders: A Clinically-Focused Systematic Review. BMC Psychiatry, 20.","DOI":"10.1186\/s12888-019-2409-8"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the Treatment of Mental Disorders and Symptoms of Mental Disorders: A Systematic Review and Meta-Analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref_72","unstructured":"U.S. Department of Veterans Affairs, and U.S. Department of Defense (2023). VA\/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder, Version 4.0."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/02698811251381246","article-title":"Phytocannabinoid Cannabidivarin Alleviates Cognitive and Social Behaviour Deficits in the Sub-Chronic Phencyclidine Rat Model of Relevance for Schizophrenia","volume":"40","author":"Grayson","year":"2025","journal-title":"J. Psychopharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-2256-0098","article-title":"Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature","volume":"57","year":"2024","journal-title":"Pharmacopsychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol Enhances Anandamide Signaling and Alleviates Psychotic Symptoms of Schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e072348","DOI":"10.1136\/bmj-2022-072348","article-title":"Balancing Risks and Benefits of Cannabis Use: Umbrella Review of Meta-Analyses of Randomised Controlled Trials and Observational Studies","volume":"382","author":"Solmi","year":"2023","journal-title":"BMJ"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"119298","DOI":"10.1016\/j.biopha.2026.119298","article-title":"Therapeutic Potential of Phytocannabinoids in Depression and Cognitive Dysfunction: Evidence from Preclinical Models","volume":"198","author":"Fonseca","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The Pharmacokinetics and the Pharmacodynamics of Cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"21m14130","DOI":"10.4088\/JCP.21m14130","article-title":"Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial","volume":"83","author":"Berger","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00213-023-06437-0","article-title":"The Effects of Cannabidiol on Worry and Anxiety Among High Trait Worriers: A Double-Blind, Randomized Placebo-Controlled Trial","volume":"240","author":"Gournay","year":"2023","journal-title":"Psychopharmacology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e13871","DOI":"10.1111\/ijcp.13871","article-title":"Consensus-Based Recommendations for Titrating Cannabinoids and Tapering Opioids for Chronic Pain Control","volume":"75","author":"Sihota","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_83","first-page":"208","article-title":"Medical Cannabis or Cannabinoids for Chronic Pain: BMJ Rapid Recommendation","volume":"106","author":"Hughes","year":"2022","journal-title":"Am. Fam. Physician"},{"key":"ref_84","first-page":"111342","article-title":"The Prevalence of Cannabis Use Disorders in People Who Use Medicinal Cannabis: A Systematic Review and Meta-Analysis","volume":"261","author":"Leung","year":"2024","journal-title":"Drug Alcohol Depend."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamapediatrics.2024.3045","article-title":"Cannabinoids Used for Medical Purposes in Children and Adolescents: A Systematic Review and Meta-Analysis","volume":"178","author":"Chhabra","year":"2024","journal-title":"JAMA Pediatr."},{"key":"ref_86","unstructured":"American Psychiatric Association (2023). Resource Document on Cannabidiols, APA."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Bilbao, A., and Spanagel, R. (2022). Medical Cannabinoids: A Pharmacology-Based Systematic Review and Meta-Analysis for All Relevant Medical Indications. BMC Med., 20.","DOI":"10.1186\/s12916-022-02459-1"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.euroneuro.2024.10.006","article-title":"Therapeutic Potential of Minor Cannabinoids in Psychiatric Disorders: A Systematic Review","volume":"91","author":"Verdouw","year":"2025","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1151\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:58:58Z","timestamp":1784901538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":88,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ph19081151"],"URL":"https:\/\/doi.org\/10.3390\/ph19081151","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}